Evotec stock heads into the open after a 1.3 percent gain

Evotec stock closed at EUR 2.84 on Xetra on September 16, 2026, marking a gain of 1.3 percent versus the previous session. Per Xetra data, the share price remained close to its recent 52-week low despite the advance, underscoring ongoing pressure on the name.

September 16, 2026 in numbers

Evotec SE (ISIN DE0005664809) saw its shares trade in a tight range around EUR 2.84 on Xetra on September 16, 2026, with the close near the lower end of the stock’s 52-week corridor in euros. According to a same-day commentary by Aktiencheck, the stock was quoted at EUR 2.842 in the session, corresponding to a 1.28 percent rise on the day as trading interest focused on elevated short positioning. The report highlighted that hedge fund Winton had significantly increased its short position, a factor that kept sentiment cautious even as the price ticked higher. Against the broader German market, the move left Evotec still lagging major indices, which have recovered more strongly from recent lows.

Today’s drivers and events

Looking at today, September 17, 2026, investors follow ongoing sector news and conference appearances that may influence Evotec, including its participation at the Morgan Stanley 24th Annual Global Healthcare Conference earlier in the week. As Investing.com reported on September 16, 2026, Evotec used the Morgan Stanley event to sharpen its corporate profile, presenting its case to healthcare investors while the stock remained near the bottom of its 52-week range. Broader macro conditions also set the backdrop: following a recent interest rate decision that strengthened the United States dollar, global risk appetite and funding conditions for growth and biotech names remain in focus, as noted by RTTNews. These elements frame today’s session for Evotec without a specific company release or scheduled earnings date falling on September 17, 2026.